BioCentury | Jun 27, 2019
Product Development

Gene therapy’s next frontier lies beyond rare, monogenic diseases

As in vivo gene therapies continue notching approvals for rare monogenic diseases, the next frontier for the modality will be in treating complex indications without obvious genetic drivers. At least seven companies have clinical or...
BioCentury | Apr 22, 2019
Distillery Therapeutics

TGFBR1 inhibition for GATA4-deficient lung cancer

DISEASE CATEGORY: Cancer INDICATION: Non-small cell lung cancer (NSCLC) Cell culture and mouse studies suggest inhibiting TGFBR1 could help treat GATA4-deficient NSCLC. In a human GATA4-deficient NSCLC cell line, a tool compound TGFBR1 inhibitor decreased...
BioCentury | Mar 29, 2019
Targets & Mechanisms

AACR moves in a myeloid direction

Myeloid cells are showing up everywhere at this year’s AACR conference, suggesting the research community is rapidly expanding the ways it can harness the cell types to improve cancer immunotherapy responses. One of those ways...
BioCentury | Feb 20, 2019
Distillery Techniques


TECHNOLOGY: Gene profiling Amplifications in GATA4 or alterations in SMAD4 could help predict survival in esophageal adenocarcinoma. In patients, whole-genome sequencing and RNA sequencing analysis of 551 esophageal adenocarcinoma samples identified associations between poor survival...
BioCentury | Aug 16, 2018
Distillery Therapeutics


INDICATION: Breast cancer Patient sample and mouse studies suggest inhibiting TRPS1 could help treat breast cancer. In tumor samples from 1,247 breast cancer patients, levels of TRPS1 were higher than in adjacent normal tissue, and...
BioCentury | Mar 2, 2018
Clinical News

sterna's SB012 meets in Phase IIa data for UC

sterna biologicals GmbH & Co. KG (Marburg, Germany) said intrarectal SB012 met the primary endpoint of improving disease activity from baseline to day 28 as measured by total Mayo Score vs. placebo in the Phase...
BioCentury | Jul 10, 2017
Distillery Techniques


TECHNOLOGY: Gene profiling A 10-gene signature in tumors could help predict survival in breast cancer. In 4,994 breast cancer patients, low tumors levels of a signature based on the expression of 10 genes -- including...
BioCentury | May 23, 2017
Distillery Techniques

Drug delivery

TECHNOLOGY: Nanoparticles Nanoparticles sensitive to endosomal esterases and linked to DNA oligomers could be used to deliver hydrophobic drug compounds and/or nucleic acid therapies for multiple diseases. The nanoparticles consisted of an internal surfactant micelle...
BioCentury | Jan 27, 2017
Emerging Company Profile

Cardiac conversion

Cell therapies that aim to reverse disease progression in heart failure and myocardial infarction by restoring cardiomyocytes are beginning to report positive clinical data, but they require frequent administration via invasive procedures. Tenaya Therapeutics Inc....
BioCentury | Dec 6, 2016
Distillery Therapeutics


INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest TRPS1 could help treat triple-negative breast cancer (TNBC). In patient samples, levels of TRPS1 were lower in tumors from TNBC patients than in tumors...
Items per page:
1 - 10 of 27